Shijian Ding

机构：Hong Kong Baptist University

发表论文 8 篇 · 总被引 43 次 · h-index 3

代表论文

• Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release (2024 · Journal of Translational Medicine · 被引 22)
• From selection to design: Reshaping aptamer discovery with artificial intelligence (2026 · Chemical Engineering Journal · 被引 9)
• Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation (2026 · Bone Research · 被引 5)
• AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for duchenne muscular dystrophy (2026 · Acta Pharmaceutica Sinica B · 被引 3)
• Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloading (2026 · Journal of Orthopaedic Translation · 被引 2)
• Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism (2026 · Nature Communications · 被引 2)